Asymchem Laboratories (Tianjin) (SHE:002821, HKG:6821) expects an up to 63% fall in 2024 profit amid lower margins and high research and development costs.
The pharmaceutical services provider forecasts an attributable net profit of between 850 million yuan and 1.05 billion yuan for 2024, down from 2.27 billion yuan in 2023, according to a Tuesday filing with the Shenzhen bourse.